MISSION Phase 1b in SLE/LN at EULAR 2021 Presentation
2021 Annual Meeting of Stockholders
For Fiscal Year Ending Dec 31, 2020
Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders–with the hope of helping people overcome their disease and live a better life. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Kezar is translating its innovative research in protein degradation (via immunoproteasome inhibition) and protein secretion (via the Sec61 translocon) to have a significant clinical impact in the most difficult-to-treat diseases. KZR-616, our selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from our protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.
Kezar Life Sciences, Inc.
4000 Shoreline Court Suite 300 South San Francisco, CA 94080
T: (650) 822-5600
Michael Wolfe IR@kezarbio.com
Computershare Trust Company, N.A. P.O. Box 505000 Louisville, KY 40233 T: 781-575-2879